Track topics on Twitter Track topics that are important to you
The Irritable Bowel Syndrome (IBS) is defined by a combination of abdominal pain, bowel dysfunction during recurrent periods of shorter or longer duration. The absence of well-defined pathophysiological marker requires a clinical definition. The most used are the Rome criteria III whose version was published in 2006 and version IV under development.
An epidemiological study conducted in 2003 in Europe in 8 countries with over 42 000 people, found on the basis of questionnaires a prevalence of 11.5% with a diagnosis of IBS of 4.8%.in the total population; the results of this study were comparable to data obtained in the USA. A French work of our team at 35 447 healthy adults found a 6.2% frequency. In all these studies, there is a very large predominance of women (sex ratio near 2), with a preponderance of subjects of the age group 40-50 years.
IBS economic weight is high, partly due to costs directly incurred by the IBS and the costs generated by associated diseases: number of visits to the general practitioner, to the specialist, the prescription and realization of complementary examinations, hospitalization, purchase drugs and work stoppage.
From a pathophysiologic perspective, IBS is now considered as a multifactorial disease involving varying degrees, depending on the individual variables, visceral hypersensitivity, disturbances of digestive motility, impaired sensorimotor way communications between the gastrointestinal tract and the central nervous system, intestinal micro-inflammation.
Our hypothesis is that the osteopathic manipulative treatment (OMT) will improve the symptomatology of IBS in patients with functional gastrointestinal disorders.
The Irritable Bowel Syndrome (IBS) is defined by the association between abdominal pain, bowel dysfunction for longer or shorter periods of time, but in any case, recurring. The absence of well-defined pathophysiological marker, requires a clinical definition. The most used are the Rome criteria III whose version was published in 2006, Version IV is under development.
Our team demonstrated in a randomized, placebo-controlled, 31 patients with refractory IBS, visceral osteopathy that is associated with a significant improvement in diarrhea, abdominal distension and abdominal pain without change constipation. This improvement was associated with a decrease in rectal sensitivity without changes of depression, time of total or segmental colonic transit. This effect persisted one year after the end of this essay.
Primary objective To evaluate the efficacy of osteopathic manipulative treatment on IBS symptoms in IBS adult patients over a 3-sessions period according to our preliminary study (73).
Secondary objectives To evaluate and to compare the results of two therapeutic modalities : osteopathic manipulative treatment and placebo manipulative treatment on
- Subjective clinical criteria: Constipation, Diarrhea, abdominal pain, bloating, topology of abdominal pain.
- Improvement of quality of life
- Decrease of depression and anxiety
- Changes in the medication after treatment
- Search for a possible practitioner effect.
Double-blind, randomized, placebo-controlled study, parallel group multicenter French study of 3 OMT sessions followed by an 18-week follow-up period.
Patients will be randomized in a 1:1 ratio to receive osteopathic manipulative treatment or placebo manipulative treatment every 2 weeks with stratification according to the IBS phenotype (IBS-C, IBS-D, IBS-M, IBS-U).
Description of research methodology
Design Double blind randomized clinical trial with a distribution of subjects in groups at a ratio (1:1) It is a double blind, multicenter, comparative, prospective, two-arms randomized study.
- One group of patients will benefit from OMT for the treatment of irritable bowel syndrome.
- One group of patients will receive a placebo manipulation therapy for the treatment of irritable bowel syndrome Schedule
The schedule will include 7 visits:
- Four medical visits: V0 (inclusion), V4 (at week 8), V5 at week 12 and V6 at week 24 respectively;
- Three osteopathic visits (V1, V2, V3) that correspond to the visceral or placebo manipulative treatment at week 2, 4, and 6, respectively.
- If patients, are not able to immediately participate to the study a screening visit (VS) could be added in order to separate the decision of participation and the beginning of the study.
Efficacy assessment The main criteria for treatment efficacy are the value of the IBS severity score. The IBS severity score was established from the self-administered questionnaire developed and validated by Francis. The French version was validated by the MAPI Research Institute. This questionnaire includes two items concerning abdominal pain and abdominal bloating (yes/no) and four visual analog scales (1-100) to assess the severity of abdominal pain, bloating, relief after stool, and impact of symptoms on quality of life. The number of days the patient suffered during the last 10 days was also recorded. The responses were used to calculate a quantitative severity score from 0 to 500 used to make a qualitative classification: severity score 75-175 = mild, 175-300 = moderate, > 300 = severe.
This questionnaire will be registered 7 times, at inclusion (V0), during each osteopathic visit (V1, V2, V3) and each medical visit (V4, V5, V6):
- Before treatment at (V0),
- During visceral manipulative treatment (V1, V2, V3)
- During the follow-up period, after visceral manipulative treatment (osteopathic or placebo),
- At 8 weeks (V4) after inclusion,
- At 12 weeks (V5) after inclusion and
- At 24 weeks (V6) at the end of follow up visit In each center, local osteopaths will be learned to provide the same placebo or osteopathic manipulation
Number of subjects chosen 210 patients Sample Size Considering that the minimal clinical difference on the primary outcome measure that would lead clinicians to change the treatment is 50 points the IBS Symptom Severity Score, and that the standard deviation of this variable is 105 points, the sample size required to detect a difference at 90% power and 5% two-sided significance level is 94 patients/group .
To allow for loss to follow up around 10%, the total sample size of the trial would will be N=210 patients.
Number of centres 7 centres are included Research period
- Inclusion period : 24 months
- Treatment period : 6 weeks
- Follow up period : 18 weeks Total research period: 30 months
Statistical analysis Descriptive Statistics
All study variables will be presented by treatment and overall, by using the appropriate descriptive statistics according to the variable nature, unless otherwise specified:
- Continuous variables: number of non-missing observations, mean, standard deviation, standard error of the mean, minimum, median, maximum.
- Categorical variables: number of non-missing observations and column percentages (N, %) in each category.
Primary efficacy endpoint Primary endpoint: Changes from baseline of IBSSS at V4, will be analyzed by mixed model of ANCOVA with patient as random factor. Baseline value of the score as well as variables a priori known to affect the score will be included in the model.
Secondary efficacy endpoints
- Secondary efficacy variables with binary outcome (i.e. responder status) will be analysed using a Chi-square or Fisher's exact test in a 2 x 2 contingency table to compare active treatment group with placebo. A two-sided overall significance level of 5 % will be used.
- Secondary efficacy variables with continuous variables (i.e. "change from baseline") will be evaluated through an analysis of covariance (ANCOVA) models with fixed effect terms for treatment group and the patient's corresponding baseline value of the parameter as a covariate. The rebound effect will be evaluated with pairwise t-test.
- Exploratory efficacy endpoints and safety endpoints will be analysed only by descriptive statistics.
For the efficacy endpoints, the following subgroup-analyses will be presented:
- Age (<65 years vs. ≥65 years).
- Baseline abdominal pain severity (pain intensity on the 11-point NRS) <5, ≥5 to <8, ≥8).
- Baseline IBS-SSS score (mild IBS: <175 score points, moderate IBS: 175 to <300 score points, severe IBS: ≥300 score points).
- BMI (<30 kg/m² vs. BMI ≥30 kg/m²).
- Osteopath effect: analysis of data according to the osteopath that practiced the manipulative treatment.
- Analysis according to the subtype of IBS (IBS with constipation, IBS with diarrhoea, Mixed IBS, Unspecified IBS).
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Irritable Bowel Syndrome
Osteopathic session, Placebo manipulative session
Not yet recruiting
Assistance Publique - Hôpitaux de Paris
Published on BioPortfolio: 2016-10-14T02:08:22-0400
A wide number of osteopathic techniques focusing on diaphragm have been proposed but, although systematically and efficiently used, there is a general lack of evidences able to clarify how...
The purpose of this study is to determine to what extent and by what physiological mechanisms Osteopathic Manipulative Medicine (OMM) affects selected conditions related to pregnancy, labo...
This study will investigate whether an eight-week regimen of osteopathic manipulative treatment will have immediate and lasting positive effects on the symptoms, functional limitation and ...
The primary purpose of this study is to evaluate the effects of BMS-562086 on small bowel and colonic transits in female subjects with diarrhea-predominant irritable bowel syndrome (D-IBS)
Little is known about acupuncture's efficacy for Irritable Bowel Syndrome (IBS). This trial uses a manualized acupuncture treatment format that closely follows clinical practice and allow...
A high proportion of patients with irritable bowel syndrome (IBS) respond to placebo in clinical trials (estimated at about 40%). We aimed to identify factors that contribute to the high placebo respo...
Osteopathic manipulative therapy (OMTh; manipulative care provided by foreign-trained osteopaths) is effective in managing pain caused by a variety of clinical conditions. Nevertheless, the physiologi...
Irritable bowel syndrome (IBS) is multifactorial in nature, and a wide range of therapies are available to manage symptoms of this common disorder.
Sex and subtype differences within patients with irritable bowel syndrome (IBS) complicate the understanding of disorder pathogenesis and hinder the design of efficacious, therapeutic interventions.
The aim of this registry was to evaluate the effects of Pycnogenol® on the main symptoms of irritable bowel syndrome (IBS) in otherwise healthy individuals.
Chronic or recurrent colonic disorders without an identifiable structural or biochemical explanation. The widely recognized IRRITABLE BOWEL SYNDROME falls into this category.
A form of group psychotherapy. It involves treatment of more than one member of the family simultaneously in the same session.
A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.
A subspecies of Bifidobacterium longum that occurs in the GASTROINTESTINAL TRACT of human infants and is used as a PROBIOTIC. It may also be used in the treatment of IRRITABLE BOWEL SYNDROME.
Licensed physicians trained in OSTEOPATHIC MEDICINE. An osteopathic physician, also known as D.O. (Doctor of Osteopathy), is able to perform surgery and prescribe medications.
Irritable Bowel Syndrome IBS
Irritable bowel syndrome (IBS) is a common but poorly understood chronic (long-term) condition where the normal functions of the bowel are disrupted. Symptoms of IBS include abdominal pain or discomfort, changes in bowel habits and bloated feelings. ...
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...